AstraZeneca slumps on report CEO is heading to Teva
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
London
SHARES in AstraZeneca fell more than 5 per cent on Thursday after the company declined to deny a media report that chief executive Pascal Soriot was about to defect to Israel-based Teva Pharmaceutical Industries.
Mr Soriot, who has led the Anglo- Swedish company since 2012, met Teva's search committee and its chairman to express his agreement to serve as its next CEO, the Calcalist financial news website said late on Wednesday.
Share with us your feedback on BT's products and services
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
20 photos that show how dramatically Singapore has changed in two decades
Singapore’s key exports up 15.3% in March from electronics surge, exceeding forecasts
